Malignant pleural mesothelioma: A comprehensive review

Cancer Control

Volumn 13, Issue 4, 2006, Pages 255-263

  Ismail Khan, Roohi ^a   Robinson, Lary A ^a   Williams, Charles C ^a   Garrett, Christopher R ^a   Bepler, Gerold ^a   Simon, George R ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CISPLATIN; CISPLATIN PLUS PEMETREXED; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; NAVELBINE; PEMETREXED; RANPIRNASE; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN; VATALANIB;

ALLERGIC REACTION; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CYTOREDUCTIVE SURGERY; DECORTICATION; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LUNG RESECTION; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PLEURA MESOTHELIOMA; PLEURECTOMY; REVIEW; THORACOSCOPY;

EID: 33750182984     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480601300402     Document Type: Review

References (22)

1. Work-Related Lung Disease Surveillance Report 2002. NIOSH Publication No. 2003-111. National Institute for Occupational Safety and Health. Section 7. Malignant Mesothelioma. Available at http://www.cdc.gov/niosh/docs/2003-111/ 2003-111.html. Accessed on September 7, 2006.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005;353:1591-1603.
3. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med. 1960;17:260-271.
4. Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-1117.
5. Carbone M, Pass HI, Miele L, et al. New developments about the association of SV40 with human mesothelioma. Oncogene. 2003;22:5173-5180.
6. Barbanti-Brodano G, Sabbioni S, Martini F, et al. Simian virus 40 infection in humans and association with human diseases: results and hypotheses. Virology.2004;318:1-9.
7. Strickler HD, Goedert JJ, Devesa SS, et al. Trends in U.S. pleural mesothelioma incidence rates following simian virus 40 contamination of early poliovirus vaccines. J Natl Cancer Inst. 2003;95:38-45.
8. Cutrone R, Lednicky J, Dunn G, et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 2005;65:10273-10279.
9. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002;29:41-50.
10. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and the diagnosis of mesothelioma. Lancet. 2003;362:1612-1616.
11. Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005;353:1564-1573.
12. van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest. 2003;123:551-561.
13. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 1997;9:367-372.
14. Stewart DJ, Martin-Ucar A, Pilling JE, et al. The effect of extent of local resection on patterns of disease progression in malignant mesothelioma. Ann Thorac Surg. 2004;78:245-252.
15. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002;29:41-50.
16. Zierhut D, Gutwein S, Munter MW, et al. Radiation therapy of mesothelioma: the Heidelberg experience and future aspects. Lung Cancer. 2004;45(suppl 1):S85-S91.
17. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644.
18. Kindler HL, Karrison T, Lu C, et al. A multicenter, double-blind, placebo-controlled randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo in patients (pts) with malignant mesothelioma (MM). Proc Annu Meet Am Soc Clin Oncol. 2005;23:7019. Abstract.
19. Mikulski SM, Costanzi JJ, Vogelzang NJ, et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol. 2002;20:274-281.
20. Pavlakis N, Vogelzang NJ. Ranpirnase - an antitumour ribonuclease: its potential role in malignant mesothelioma. Expert Opin Biol Ther. 2006;6:391-399.
21. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54-65.
22. Lee TT, Everett DL, Shu HK, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183-1189.